BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1254 related articles for article (PubMed ID: 19108784)

  • 1. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
    Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
    Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Int J Rheum Dis; 2018 May; 21(5):922-929. PubMed ID: 29671942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are All Biologics the Same? Optimal Treatment Strategies for Patients With Early Rheumatoid Arthritis: Systematic Review and Indirect Pairwise Meta-Analysis.
    Albert DA
    J Clin Rheumatol; 2015 Dec; 21(8):398-404. PubMed ID: 26226612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC; Weisman MH; Kavanaugh AF; Cohen SB; Pavelka K; van Vollenhoven R; Sharp J; Perez JL; Spencer-Green GT
    Arthritis Rheum; 2006 Jan; 54(1):26-37. PubMed ID: 16385520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone.
    Durez P; Malghem J; Nzeusseu Toukap A; Depresseux G; Lauwerys BR; Westhovens R; Luyten FP; Corluy L; Houssiau FA; Verschueren P
    Arthritis Rheum; 2007 Dec; 56(12):3919-27. PubMed ID: 18050189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
    Chen DY; Chou SJ; Hsieh TY; Chen YH; Chen HH; Hsieh CW; Lan JL
    J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.
    Alonso-Ruiz A; Pijoan JI; Ansuategui E; Urkaregi A; Calabozo M; Quintana A
    BMC Musculoskelet Disord; 2008 Apr; 9():52. PubMed ID: 18419803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
    Weinblatt ME; Mease P; Mysler E; Takeuchi T; Drescher E; Berman A; Xing J; Zilberstein M; Banerjee S; Emery P
    Arthritis Rheumatol; 2015 Oct; 67(10):2591-600. PubMed ID: 26138593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Ouyang D; Ma YZ; Zou J; Wang YL; Chen Z; Yang YY; Zou B; Li X; Cao JZ
    Front Pharmacol; 2022; 13():911810. PubMed ID: 35991879
    [No Abstract]   [Full Text] [Related]  

  • 18. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.
    Wiens A; Venson R; Correr CJ; Otuki MF; Pontarolo R
    Pharmacotherapy; 2010 Apr; 30(4):339-53. PubMed ID: 20334454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.
    Maini RN; Breedveld FC; Kalden JR; Smolen JS; Furst D; Weisman MH; St Clair EW; Keenan GF; van der Heijde D; Marsters PA; Lipsky PE;
    Arthritis Rheum; 2004 Apr; 50(4):1051-65. PubMed ID: 15077287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
    Braun J; Kästner P; Flaxenberg P; Währisch J; Hanke P; Demary W; von Hinüber U; Rockwitz K; Heitz W; Pichlmeier U; Guimbal-Schmolck C; Brandt A;
    Arthritis Rheum; 2008 Jan; 58(1):73-81. PubMed ID: 18163521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.